ImmunityBio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the 2026 Annual Meeting of Stockholders held by ImmunityBio, Inc. on June 9, 2026. The filing details the results of shareholder votes regarding director elections and the ratification of the independent registered public accounting firm.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events and does not contain financial performance data.
Material Changes and Voting Results
As of April 13, 2026, the company had 1,047,345,861 shares of Common Stock outstanding. Approximately 85% of these shares (885,167,059) were represented at the meeting, establishing a quorum.
1. Election of Nine Directors
All nine nominees were re-elected for a one-year term expiring at the 2027 annual meeting. The voting results were as follows:
| Nominee | Votes "For" | Votes "Withheld" | Broker Non-Votes |
|---|---|---|---|
| Patrick Soon-Shiong, M.D. | 714,631,732 | 19,014,153 | 151,521,174 |
| Cheryl L. Cohen | 731,554,649 | 2,091,236 | 151,521,174 |
| Richard Adcock | 731,960,821 | 1,685,064 | 151,521,174 |
| Michael D. Blaszyk | 722,575,150 | 11,070,735 | 151,521,174 |
| Wesley Clark | 729,527,285 | 4,118,600 | 151,521,174 |
| Linda Maxwell, M.D. | 717,976,024 | 15,669,861 | 151,521,174 |
| Christobel Selecky | 722,387,537 | 11,258,348 | 151,521,174 |
| Barry J. Simon, M.D. | 731,770,436 | 1,875,449 | 151,521,174 |
| Bruce Wendel | 732,149,734 | 1,496,151 | 151,521,174 |
2. Ratification of Independent Auditor
Stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
| Vote Type | Count |
|---|---|
| Votes "For" | 882,420,139 |
| Votes "Against" | 1,675,960 |
| Abstentions | 1,070,960 |
| Broker Non-Votes | 0 |
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Shareholder Participation: Approximately 85% of outstanding shares were represented at the 2026 Annual Meeting.
- Board Composition: All nine director nominees were successfully re-elected, with Patrick Soon-Shiong, M.D. receiving the highest number of "Withheld" votes (19,014,153).
- Auditor Approval: Deloitte & Touche LLP was ratified with overwhelming support (882 million votes "For" vs. 1.6 million "Against").
- Capital Structure: As of April 13, 2026, there were 1,047,345,861 shares of Common Stock outstanding.